Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling

Bilal, Hajira; Tait, Jessica R; Lang, Yinzhi; Zhou, Jieqiang; Bergen, Phillip J; Peleg, Anton Y; Bulitta, Jürgen B; Oliver, Antonio; Nation, Roger L; Landersdorfer, Cornelia B

(2022), ANTIMICROB AGENTS CH, 66(3), e02203-21

DOI: 101128/aac02203-21

Long-Term Outcomes in Patients on Life-Long Antibiotics: A Five-Year Cohort Study

Kiss, Christopher; Connoley, Declan; Connelly, Kathryn; Horne, Kylie; Korman, Tony; Woolley, Ian; Lau, Jillian SY

(2022), ANTIBIOTICS-BASEL, 11(1), 62

DOI: 103390/antibiotics11010062

Successful expanded clinic network collaboration and patient tracing for retention in HIV care

Bhatt, Shivani; Bryant, Mellissa; Lau, Helen; Tee, Ban-Kiem; Eu, Beng; O’Bryan, Jessica; Woolley, Ian; Mitchell, Jeni; Street, Alan; Dobinson, Sheranne; Medland, Nicholas; Lamb, Judy; Mahony, Andrew; Tramontana, Adrian; Lim, Lyn-Li; Wade, Amanda; Roder, C

(2022), AIDS RES THER, 19(1), 61

DOI: 101186/s12981-022-00476-x

The Impact of the COVID-19 Pandemic on People with HIV in Victoria, Australia: 1 Year Later

Weerasuria, Mihiri; Ko, Christy; Ehm, Adam; O'Bryan, Jessica; McMahon, James; Woolley, Ian; Hoy, Jennifer; Lau, Jillian

(2022), AIDS RES HUM RETROV, 38(11), 875-877

DOI: 101089/AID20220048

Neurotoxicity with high-dose disulfiram and vorinostat used for hiv latency reversal

Mcmahon, James H; Evans, Vanessa A; Lau, Jillian SY; Symons, Jori; Zerbato, Jennifer M; Chang, Judy; Solomon, Ajantha; Tennakoon, Surekha; Dantanarayana, Ashanti; Hagenauer, Michelle; Lee, Sulggi; Palmer, Sarah; Fisher, Katie; Bumpus, Namandje; Heck,

(2022), AIDS, 36(1), 75-82

DOI: 101097/QAD0000000000003091

Multidrug-resistant Klebsiella pneumoniae: a retrospective study in Manaus, Brazil

Nakamura-Silva, Rafael; Cerdeira, Louise; Oliveira-Silva, Mariana; da Costa, Karen Regina Carim; Sano, Elder; Fuga, Bruna; Moura, Quézia; Esposito, Fernanda; Lincopan, Nilton; Wyres, Kelly; Pitondo-Silva, André

(2022), ARCH MICROBIOL, 204(4), 202

DOI: 101007/s00203-022-02813-0

Latent class analysis of sexual behaviours and attitudes to sexually transmitted infections among gay and bisexual men using PrEP

Traeger MW, Murphy D, Ryan KE, Asselin J, Cornelisse VJ, Wilkinson AL, Hellard ME, Wright EJ, Stoové MA

(2022), AIDS Behav, 26(6), 1808-20

DOI: 101007/s10461-021-03529-w

Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data

Traeger MW, Guy R, Asselin J, Patel P, Carter A, Wright EJ, Grulich A, McManus H, Fairley CK, Chow EPF, McNulty A, Finlayson R, Bell C, Owen L, Marshall L, Russell D, O'Donnell D, Donovan B, Hellard ME, Stoové MA; Australian Collaboration for Coordinated

(2022), Lancet Infect Dis, 22(8), 1231-41

DOI: 101016/s1473-3099(22)00175-x

"How PrEPared are you?": Knowledge of and attitudes toward PrEP among overseas-born and newly arrived gay, bisexual, and other men who have sex with men in Australia

Sudarto B, Chow EPF, Medland N, Fairley CK, Wright EJ, Armishaw J, Price B, Phillips TR, Ong JJ

(2022), Front Public Health, 10, 946771

DOI: 103389/fpubh2022946771

High effectiveness of broad access direct-acting antiviral therapy for hepatitis C in an Australian real-world cohort: The REACH-C Study

Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Doyle JS, Davies J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group

(2022), Hepatol Commun, 6(3), 496-512

DOI: 101002/hep41826

Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020

Wilkinson AL, van Santen DK, Traeger MW, Sacks-Davis R, Asselin J, Scott N, Harney BL, Doyle JS, El-Hayek C, Howell J, Bramwell F, McManus H, Donovan B, Stoové M, Hellard M, Pedrana A

(2022), Int J Drug Policy, 103, 103655

DOI: 101016/jdrugpo2022103655

Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia

Wallace J, Xiao Y, Howell J, Thompson A, Allard N, Adamson E, Richmond J, Hajarizadeh B, Eagle M, Doyle J, Hellard M

(2022), BMC Public Health, 22(1), 536

DOI: 101186/s12889-022-12907-5

Interventions to eliminate hepatitis C: which ones suit your community?

Wade AJ, Doyle JS

(2022), LANCET GASTROENTEROL, 7(5), 383-4

DOI: 101016/s2468-1253(22)00010-3

Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs

Traeger MW, van Santen DK, Sacks-Davis R, Asselin J, Carter A, Doyle JS, Pedrana A, Wilkinson AL, Howell J, Thatcher R, Didlick J, Donovan B, Guy R, Hellard ME, Stoové MA; Australia Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually

(2022), J VIRAL HEPATITIS, 29(10), 908-18

DOI: 101111/jvh13723

Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size

Rasmussen TA, Ahuja SK, Kuwanda L, Vjecha MJ, Hudson F, Lal L, Rhodes A, Chang J, Palmer S, Auberson-Munderi P, Mugerwa H, Wood R, Badal-Faesen S, Pillay S, Mngqibisa R, LaRosa A, Hildago J, Petoumenos K, Chiu C, Lutaakome J, Kitonsa J, Kabaswaga E, Pala

(2022), Clin Infect Dis, 75(10), 1781-91

DOI: 101093/cid/ciac249

Point-of-Care Diagnostics for Diagnosis of Active Syphilis Infection: Needs, Challenges and the Way Forward

Pham MD, Ong JJ, Anderson DA, Drummer HE, Stoové M

(2022), INT J ENV RES PUB HE, 19(13), 8172

DOI: 103390/ijerph19138172

Care navigation increases initiation of hepatitis C treatment after release from prison in a prospective randomized controlled trial: The C-LINK Study

Papaluca T, Craigie A, McDonald L, Edwards A, Winter R, Hoang A, Pappas A, Waldron A, McCoy K, Stoové M, Doyle J, Hellard M, Holmes J, MacIsaac M, Desmond P, Iser D, Thompson AJ

(2022), OPEN FORUM INFECT DI, 9(8), ofac350

DOI: 101093/ofid/ofac350

Screening for risky drinkers among hospitalised inpatients using the AUDIT: A feasibility, point prevalence and data linkage study

O'Brien H, Di Rico R, Dean E, Smoker G, Lloyd-Jones M, McKechnie M, Dietze PM, Doyle JS

(2022), Drug Alcohol Rev, 41(1), 293-302

DOI: 101111/dar13343

Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial

McMahon JH, Lau JSY, Coldham A, Roney J, Hagenauer M, Price S, Bryant M, Garlick J, Paterson A, Lee SJ, O'Bryan J, Hearps A, Tachedjian G, Pinskier H, Phillips C, Garrow S, Pinskier N, Melvin R, Blakeway L, Wisniewski JA, Byers S, Badoordeen GZ, Pereira S

(2022), EClinicalMedicine, 54, 101703

DOI: 101016/jeclinm2022101703

Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study

Howell J, Van H, Pham M, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan G, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson AJ, Drummer HE, Anderson D

(2022), Clin Liver Dis, 20(4), 136-9

DOI: 101002/cld1261

2 3 4 5